Puma Biotechnology, Inc. (PBYI) Earnings History
Annual and quarterly earnings data from 2007 to 2025
Loading earnings history...
PBYI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PBYI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 74.5% | 16.3% | 13.6% |
| 2024 | 72.1% | 13.4% | 13.1% |
| 2023 | 73.4% | 13.9% | 9.2% |
| 2022 | 75.8% | 10.4% | 0.0% |
| 2021 | 74.8% | 0.5% | -11.5% |
Download Data
Export PBYI earnings history in CSV or JSON format
Free sign-in required to download data
Puma Biotechnology, Inc. (PBYI) Earnings Overview
As of May 8, 2026, Puma Biotechnology, Inc. (PBYI) reported trailing twelve-month net income of $24M, reflecting -1.6% year-over-year growth. The company earned $0.48 per diluted share over the past four quarters, with a net profit margin of 13.6%.
Looking at the long-term picture, PBYI's historical earnings data spans multiple years. The company achieved its highest annual net income of $31M in fiscal 2025, representing a new all-time high.
Puma Biotechnology, Inc. maintains positive profitability with a gross margin of 74.5%, operating margin of 16.3%, and net margin of 13.6%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), TGTX ($462M net income, 72.6% margin), PTCT (-$187M net income, 39.4% margin), PBYI has outperformed on profitability metrics. Compare PBYI vs RCUS →
PBYI Earnings vs Peers
Earnings metrics vs comparable public companies
PBYI Historical Earnings Data (2007–2025)
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $31M | +2.8% | $37M | $0.61 | 13.6% | 16.3% |
| 2024 | $30M | +40.2% | $31M | $0.62 | 13.1% | 13.4% |
| 2023 | $22M | +1079450.0% | $33M | $0.45 | 9.2% | 13.9% |
| 2022 | $2,000 | +100.0% | $24M | $0.02 | 0.0% | 10.4% |
| 2021 | -$29M | +51.5% | $1M | $-0.72 | -11.5% | 0.5% |
| 2020 | -$60M | +20.6% | -$30M | $-1.52 | -26.7% | -13.5% |
| 2019 | -$76M | +33.5% | -$76M | $-2.13 | -27.8% | -27.8% |
| 2018 | -$114M | +61.1% | -$95M | $-2.99 | -45.3% | -37.7% |
| 2017 | -$292M | -5.8% | -$292M | $-7.86 | -1054.2% | -1055.6% |
| 2016 | -$276M | -15.3% | -$277M | $-8.29 | - | - |
See PBYI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PBYI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PBYI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPBYI — Frequently Asked Questions
Quick answers to the most common questions about buying PBYI stock.
Is PBYI growing earnings?
PBYI EPS of $0.48 reflects slowing growth at -1.6%, below the 5-year CAGR of N/A. TTM net income is $24M. Expansion rate has moderated.
What are PBYI's profit margins?
Puma Biotechnology, Inc. net margin is +13.6%, with operating margin at +16.3%. Margins sit within typical range for the sector.
How consistent are PBYI's earnings?
PBYI earnings data spans 2007-2025. The current earnings trend is -1.6% YoY. Historical data enables comparison across business cycles.